CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. QCOM
2. MU
3. CBRS
4. HTZ
5. FDX
6. USO
7. SPY
8. KBH
9. LAES
10. HON

Go back to CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
CEL-SCI CORPORATION (NYSE: CVM) Delayed: 1.00 -0.02 (1.96%)
Previous Close $1.02    52 Week High $0.66 
Open $1.03    52 Week Low $0.20 
Day High $1.16    P/E N/A 
Day Low $1.00    EPS $-0.34 
Volume 621,781